Hot Topics: Oral Contraceptives and Migraine

Who is most at risk for stroke? There is a higher prevalence of migraine among women, compared with men, so it’s important to consider risks as they relate to women’s health issues—namely when prescribing oral contraceptives. This is most important when it comes to patients that have migraine with aura, which is about 30% of the migraine population. “Although the baseline risk of stroke in patients with migraine with aura is very low, their risk is twice that of an average person,” says Dr. Katherine Hamilton, MD, of the University of Pennsylvania. Adding in estrogen-based oral contraceptives can further increase...

Neuromodulation as a Treatment for Migraine

Umer Najib, MD, FAHS, shares who is a suitable candidate for non-invasive neuromodulation and explains how to gauge treatment success Umer Najib, MD, FAHS, is an assistant professor in neurology at the Rockefeller Neuroscience Institute at West Virginia University and program director for the Headache Medicine Fellowship. He recently spoke on neuromodulation as a potential treatment for patients with migraine. Watch the full interview from the 2018 Scottsdale Headache Symposium here: https://www.youtube.com/watch?v=i24nUkRWPMI Neuromodulation is the modulation or manipulation of the central pain system via invasive or non-invasive electrical pulses or magnetic pulses. Najib highlighted three types of FDA-approved non-invasive neuromodulation:...

Special Interest Section Profile: Migraine and Vascular Disease

Find out more about how the Migraine and Vascular Disease Special Interest Section works to research the relationship between migraine and vascular disease The American Headache Society is home to a diverse selection of Special Interest Sections that connect members with shared expertise and interests to collaborate on research efforts, develop practice models and provide multidisciplinary participation in support of the Society’s mission. https://www.youtube.com/watch?v=a_4dfuFvPkc&f= The Special Interest Section focused on Migraine and Vascular Disease aims to improve the lives of those living with migraine who are also affected by vascular disease. The Migraine and Vascular Disease section strives to help...

Sleep, Migraine and Improved Patient Outcomes

By Angeliki Vgontzas, MD The value of educating patients on healthy sleep habits Poor sleep habits and migraine continue to be linked as more advanced technology allows physicians to reveal a stronger connection. Most physicians can attest that migraine patients consistently present with poor sleep habits. But what isn’t exactly clear is if something is happening during the migraine attack that is interrupting sleep, or if poor sleep can trigger more attacks. “This is a really exciting time for sleep and migraine research because, as imaging continues to advance and clinicians are able to hone in on portions of the...

Next Generation Migraine Therapies – New York

The Next Generation Migraine Therapies (NGMT) initiative is a comprehensive program designed to provide a multi-faceted approach to migraine education offered at no cost to healthcare providers including neurologists, primary care physicians and advanced practice providers. Brought to you by the American Headache Society, the program covers topics around the diagnosis and treatment of migraine, and updates on the latest science around the disease. Through a mix of regional in-person workshops, NGMT is designed to engage participants through didactic and interactive case study workshops. Register at no cost to attend our New York event here.

  • Diagnosis and treatment
    • Acute and Preventative treatment options
    • What works well and what are the unmet needs?
    • Risks for migraine progression
  • The latest science
    • State of the art therapeutic options
    • Multi format administration options
    • CGRP receptors as a target for small molecules: GPANTs
    • Immunology, antibodies, and monoclonal antibodies
    • Neuromodulation update
  • Answer questions such as
    • How can peripherally acting drugs treat migraine?
    • What do I need to know about monoclonal antibodies that treat migraine?
    • What do I need to know to identify appropriate patients for the appropriate therapeutic option?
    • How do I best identify appropriate patients for these emerging therapies?

Register Now

Next Generation Migraine Therapies – Dallas

The Next Generation Migraine Therapies (NGMT) initiative is a comprehensive program designed to provide a multi-faceted approach to migraine education offered at no cost to healthcare providers including neurologists, primary care physicians and advanced practice providers. Brought to you by the American Headache Society, the program covers topics around the diagnosis and treatment of migraine, and updates on the latest science around the disease. Through a mix of regional in-person workshops, NGMT is designed to engage participants through didactic and interactive case study workshops. Register at no cost to attend our Dallas event here.

  • Diagnosis and treatment
    • Acute and Preventative treatment options
    • What works well and what are the unmet needs?
    • Risks for migraine progression
  • The latest science
    • State of the art therapeutic options
    • Multi format administration options
    • CGRP receptors as a target for small molecules: GPANTs
    • Immunology, antibodies, and monoclonal antibodies
    • Neuromodulation update
  • Answer questions such as
    • How can peripherally acting drugs treat migraine?
    • What do I need to know about monoclonal antibodies that treat migraine?
    • How do I best identify appropriate patients for the appropriate therapeutic option?
    • What do I need to know to identify appropriate patients for these emerging therapies?

Register Now

Next Generation Migraine Therapies – San Diego

The Next Generation Migraine Therapies (NGMT) initiative is a comprehensive program designed to provide a multi-faceted approach to migraine education offered at no cost to healthcare providers including neurologists, primary care physicians and advanced practice providers. Brought to you by the American Headache Society, the program covers topics around the diagnosis and treatment of migraine, and updates on the latest science around the disease. Through a mix of regional in-person workshops, NGMT is designed to engage participants through didactic and interactive case study workshops. Register at no cost to attend our San Diego event here.

  • Diagnosis and treatment
    • Acute and Preventative treatment options
    • What works well and what are the unmet needs?
    • Risks for migraine progression
  • The latest science
    • State of the art therapeutic options
    • Multi format administration options
    • CGRP receptors as a target for small molecules: GPANTs
    • Immunology, antibodies, and monoclonal antibodies
    • Neuromodulation update
  • Answer questions such as
    • How can peripherally acting drugs treat migraine?
    • What do I need to know about monoclonal antibodies that treat migraine?
    • What do I need to know to identify appropriate patients for the appropriate therapeutic option?
    • How do I best identify appropriate patients for these emerging therapies?

Register Now

Next Generation Migraine Therapies

The Next Generation Migraine Therapies (NGMT) initiative is a comprehensive program designed to provide a multi-faceted approach to migraine education offered at no cost to healthcare providers. Brought to you by the American Headache Society, the program covers diagnosis and treatment of migraine, and updates on the latest science. Through a mix of regional in-person workshops, NGMT is designed to engage participants through didactic and case study workshops, including interactive education elements, communication toolkits, and takeaway resources.

Next Generation Migraine Therapies – San Diego, April 6, 2019

Next Generation Migraine Therapies – Dallas, May 18, 2019

Next Generation Migraine Therapies – New York, June 8, 2019

To view the program brochure including preliminary program agenda, please click here.

What Allodynia Tells us About Migraine: Q&A With David Dodick, MD, FAHS

How three factors associated with allodynia, as outlined by the MAST Study, affect migraine treatment options Allodynia is the experience when ordinarily nonpainful stimuli, like a light touch and brushing your hair, becomes painful. David Dodick, MD, FAHS, professor of neurology at the Mayo Clinic and Chair of the American Migraine Foundation, says 40% to 70% of people experience allodynia when having a migraine attack. We sat down with Dr. Dodick to discuss what we learned about allodynia from the Migraine in America Symptoms and Treatment (MAST) Study. https://www.youtube.com/watch?v=dvo4nNMPTVA Why is allodynia important and what can it tell us? Allodynia...

OnabotulinumtoxinA as a Treatment for Chronic Migraine

Carrie Dougherty, MD, FAHS, shares who is a suitable candidate and how providers can help patients access care Dr. Carrie Dougherty, Assistant Professor in the Department of Neurology and the Program Director of Headache Medicine Fellowship at MedStar Georgetown University Hospital, recently spoke on onabotulinumtoxinA as a potential treatment for patients with chronic migraine. Watch the full interview from the 2018 Scottsdale Headache Symposium here: https://www.youtube.com/watch?v=4ShnM_XgR9c OnabotA is different from other types of preventive treatments: It is a procedure that is administered every 12 weeks as an ongoing prevention method. The procedure is comprised of 31 injections located in the...